Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188
Publication/Presentation Date
5-2020
Volume
38
Issue
15
Published In/Presented At
DOI: 10.1200/JCO.2020.38.15_suppl.5019
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
Department(s)
Administration and Leadership
Document Type
Article
COinS